Role of palbociclib in the treatment of hormone receptor-positive HER2-negative metastatic breast cancer. Generalizing results of randomized trials and real clinical practice

Медицинский совет

E. I. Khatkova¹  E. M. Kolyago¹  E. A. Arutyunyan²  P. S. Feoklistova²  L. G. Zhukova²  K. S. Grechukhina²  S. A. Smolin² 

[1] Federal State Budgetary Institution «National Medical Research Center for Children’s Hematology, Oncology and Immunology named after Dmitry Rogachev» of the Ministry of Health of the Russian Federation.;State Budgetary Health Institution «Loginov Moscow Clinical Research Center» of the Moscow Department of Health.;

关键词: palbociclib;    breast cancer;    endocrinotherapy;   

DOI  :  10.21518/2079-701X-2019-10-56-62

来源: DOAJ

【 摘 要 】

Palbociclib is the first-in-class drug of CDK 4/6 inhibitors group. The use of palbociclib in combination with endocrinotherapy (ET) opens up new possibilities for the treatment of metastatic hormone receptor-positive (HRP+) HER2-negative (HER2-) breast cancer (mBC). Palbociclib has gained world attention and is included in all clinical guidelines, both international and domestic, as a new standard of first- and second-line therapy of HRP+ HER2- mBC. The article presents the updated results of PALOMA-2 and PALOMA-3 studies and the results of use of palbociclib in combination with ET in real clinical practice.

【 授权许可】

Unknown